The anti-clotting drug apixaban which is being developed by USA-based drug majors Bristol-Myers Squibb and Pfizer, has met its primary safety and efficacy goals in a mid-stage trial involving deep vein thrombosis patients, according to CNN Money and other media reports.
The 12-week Phase II study recruited 520 DVT patients who were provided with one of four treatment regimens, either 5mg or 10mg of apixaban twice a day, 20mg once daily or an injectable anticoagulent plus warfarin in the control group. The results showed that the rate of DVT incidents in each of the three drug-treated groups were 6%, 5.6% and 2.6%, respectively, compared with 4.2% in the control arm. The bleeding rates across the four treatment groups were comparable (8.6%, 4.5%, 7.3% and 7.9%), while none of the three drug regimens were associated with liver toxicity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze